A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
NCT05337553 · RESILIENT Phase 3Active, not recruiting
- Lead sponsor
- Biohaven Pharmaceuticals, Inc. (Industry)
- Enrollment
- 269 (actual)
- Start date
- 6 Jul 2022
- Primary completion
- 25 Sep 2024 (actual)
- Study completion
- 1 Dec 2027
- Last update posted
- 1 Jun 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- taldefgrobep alfa Drug
- Placebo Drug
Conditions and primary outcome
- Spinal Muscular Atrophy
- Neuromuscular Diseases
- SMA
Primary outcome
Efficacy of taldefgrobep alfa compared to placebo in change in the 32 item Motor Function Measure (MFM-32) total score (Baseline to Week 48)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT05337553.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05337553 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.